Morgan Stanley Has Lowered Expectations for Neurocrine Biosciences (NASDAQ:NBIX) Stock Price

Neurocrine Biosciences (NASDAQ:NBIX) had its price target lowered by Morgan Stanley from $196.00 to $182.00 in a research report issued on Thursday,Benzinga reports. The firm presently has an “equal weight” rating on the stock. Morgan Stanley’s price objective points to a potential upside of 19.41% from the stock’s previous close.

Several other analysts have also recently issued reports on the stock. Needham & Company LLC upped their price objective on shares of Neurocrine Biosciences from $200.00 to $204.00 and gave the company a “buy” rating in a research note on Friday, July 31st. Weiss Ratings cut Neurocrine Biosciences from a “buy (b)” rating to a “buy (b-)” rating in a report on Tuesday. Citigroup upped their price target on Neurocrine Biosciences from $246.00 to $249.00 and gave the company a “buy” rating in a research report on Friday, July 31st. Wells Fargo & Company increased their price target on Neurocrine Biosciences from $175.00 to $200.00 and gave the company an “overweight” rating in a report on Friday, July 17th. Finally, The Goldman Sachs Group began coverage on Neurocrine Biosciences in a research note on Tuesday, June 2nd. They set a “buy” rating and a $213.00 price objective on the stock. One equities research analyst has rated the stock with a Strong Buy rating, nineteen have given a Buy rating and four have assigned a Hold rating to the company’s stock. According to data from MarketBeat, Neurocrine Biosciences currently has a consensus rating of “Moderate Buy” and an average price target of $200.86.

Neurocrine Biosciences Stock Down 2.6%

Shares of Neurocrine Biosciences stock traded down $4.07 during trading hours on Thursday, reaching $152.42. 602,944 shares of the company’s stock were exchanged, compared to its average volume of 1,204,314. The business has a fifty day moving average of $168.54 and a two-hundred day moving average of $148.10. The company has a market capitalization of $15.49 billion, a P/E ratio of 22.36, a price-to-earnings-growth ratio of 0.57 and a beta of 0.39. Neurocrine Biosciences has a 1 year low of $122.14 and a 1 year high of $186.12.

Insider Activity

In related news, Director Stephen A. Sherwin sold 25,000 shares of the company’s stock in a transaction that occurred on Friday, June 5th. The stock was sold at an average price of $165.32, for a total value of $4,133,000.00. Following the transaction, the director directly owned 15,860 shares in the company, valued at approximately $2,621,975.20. This represents a 61.18% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Darin Lippoldt sold 10,000 shares of the stock in a transaction that occurred on Thursday, July 9th. The stock was sold at an average price of $179.60, for a total value of $1,796,000.00. Following the completion of the transaction, the insider owned 54,729 shares of the company’s stock, valued at $9,829,328.40. The trade was a 15.45% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 391,612 shares of company stock worth $61,858,105 over the last quarter. 4.60% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Neurocrine Biosciences

Large investors have recently modified their holdings of the business. Royal Bank of Canada lifted its position in Neurocrine Biosciences by 36.7% in the first quarter. Royal Bank of Canada now owns 82,810 shares of the company’s stock valued at $9,158,000 after buying an additional 22,224 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in shares of Neurocrine Biosciences by 60.6% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 14,783 shares of the company’s stock valued at $1,647,000 after acquiring an additional 5,577 shares during the last quarter. NewEdge Advisors LLC raised its stake in shares of Neurocrine Biosciences by 56.3% in the 1st quarter. NewEdge Advisors LLC now owns 7,630 shares of the company’s stock valued at $844,000 after acquiring an additional 2,747 shares during the period. Empowered Funds LLC purchased a new stake in shares of Neurocrine Biosciences in the 1st quarter valued at approximately $1,333,000. Finally, Geneos Wealth Management Inc. lifted its holdings in shares of Neurocrine Biosciences by 143.6% in the 1st quarter. Geneos Wealth Management Inc. now owns 229 shares of the company’s stock worth $25,000 after acquiring an additional 135 shares during the last quarter. Institutional investors and hedge funds own 92.59% of the company’s stock.

More Neurocrine Biosciences News

Here are the key news stories impacting Neurocrine Biosciences this week:

• Positive Sentiment: Positive INGREZZA data: Results from the KINECT-PRO Phase 4 study showed sustained improvements in quality of life, daily functioning and tardive dyskinesia movement severity. About 58% of patients reached the study’s threshold for symptomatic remission at Week 24, supporting INGREZZA’s commercial durability. KINECT-PRO study results
• Positive Sentiment: Analysts remain constructive: Neurocrine received an average “Moderate Buy” recommendation. Recent analyst price targets include $185 from JPMorgan, $191 from RBC and $213 from Goldman Sachs, indicating that many analysts still see upside based on the company’s growth outlook. Analyst recommendation
• Neutral Sentiment: Strong operating momentum but higher costs: Second-quarter revenue increased 39% year over year to $959 million, and 2026 INGREZZA sales guidance was raised to $2.825 billion–$2.875 billion. However, higher research and selling expenses, lower cash balances and acquisition-related financing are increasing investor scrutiny of margins, integration and capital allocation. NBIX stock analysis
• Negative Sentiment: Vykat XR safety concerns are weighing on sentiment: Prader-Willi syndrome experts cited serious adverse events associated with the drug, prompting renewed warnings following the Soleno acquisition. Investors may be concerned about regulatory scrutiny, adoption, potential liability and the financial return from the deal. Vykat XR safety concerns

About Neurocrine Biosciences

Neurocrine Biosciences (NASDAQ: NBIX) is a biopharmaceutical company based in San Diego, California, focused on developing treatments for neurological, endocrine and neuropsychiatric disorders. Since its founding in 1992, the company has pursued a research‐driven strategy aimed at addressing unmet medical needs in movement disorders, reproductive health and central nervous system conditions. Neurocrine’s operations encompass drug discovery, clinical development and commercialization activities.

The company’s lead marketed product, Ingrezza™ (valbenazine), is indicated for the treatment of tardive dyskinesia, a movement disorder associated with long-term antipsychotic use.